RM-046, a First-in-class, Mutant-Selective, and Oral KRASQ61H(ON) Inhibitor That Drives Tumor Regression in Preclinical Models and Validates KRASQ61H As a Therapeutic TargetYu C. Yang,Severin Thompson,David Montgomery, Antonio J. Quinones, Xing Wei, Benjamin Madej,Aidan Tomlinson, Nataliya T. Shifrin,Alexander McNamara,Ethan Ahler,Laura L. McDowell, Michael Flagella, John Setser,Stephanie Chang,Zhican Wang,Zhengping Wang,Jun Huang, Steve Ballmer, Shaong Li,Andreas Buckl,Elena Koltun,Adrian Gill,Jingjing Jiang,Mallika Singh,Jacqueline A. SmithCancer Research（2023）引用 2|浏览26AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
